N/A Completed N=48 Randomized Quadruple-blind Treatment

Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis

Source: ClinicalTrials.gov NCT02368093 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Mar 2015

Primary outcomePrimary: Good European League Against Rheumatism (EULAR) Therapeutic Response Rate — 6; 4 participants

Summary

Rheumatoid arthritis were randomized to a 6-month treatment of oral dextromethorphan hydrobromide or placebo as an add-on therapy to traditional disease-modifying anti-rheumatic drugs (DMARDs). Disease activity were assessed.

Outcome Measures

Outcome	Result	p-value
PRIMARY Good European League Against Rheumatism (EULAR) Therapeutic Response Rate	6; 4	—

Eligibility Criteria

Inclusion Criteria

Patients fulfilling the 2010 criteria of the American College of Rheumatology (ACR) for RA

Exclusion Criteria

Receive biological therapy for RA, including Etanercept, Adalimumab, Golimumab, Tocilizumab, Rituximab, Abatacept.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02368093). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.